Xenova Group plc., of Slough, England, raised $4.85 million in gross proceeds from a direct placement of 1.29 million American Depository Shares at $3.75 per share primarily to existing stockholders. * Zynaxis Inc., of Malvern, Pa., entered into an agreement with Frankfurt, Germany-based Hoechst AG to evaluate the former's Zyn-linker delivery systems for use with the latter's oligonucleotide drugs, which are designed to affect intracellular activities

The move is subject to shareholder approval. * Gliatech Inc., of Cleveland, received $200,000 in funding from the National Institutes of Health (NIH) for development of histamine receptor agents for treatment of anxiety, insomnia and eating disorders...The additional shares were registered to cover overallotments and were sold to the underwriters, Hambrecht & Quist LLC and Dillon, Read & Co., both of New York, and Van Kasper & Co., of San Francisco

The company's first two assays, used to assess thyroid function, already were cleared by the FDA...Oncor said it intends to address the panel's concerns...Ostex said it took the action because Boehringer Mannheim failed to market the Osteomark bone resorption test per the agreement

Forty- five days after the closing, the shares are convertible to Cortex common stock at $2.825 per share or 85 percent of market value of the stock, whichever is lower...Chiron Biocine, a unit of Emeryville-based Chiron Corp., also has an option to license Iscoms for use with other vaccines, such as cytomegalovirus and hepatitis C. Isotec is a subsidiary of CSL Ltd., of Melbourne, Australia. * Neoprobe Corp., of Dublin, Ohio, reached an agreement with Nordion Europe S.A...StaphGAM, a polyclonal

The move to the larger facility comes after the company's NMP22 Test Kit for bladder cancer was recommended for approval. * Neoprobe Corp., of Dublin, Ohio, said a preliminary examination of Phase III data of its RIGScan CR49 product suggested results are consistent with those seen in a Phase II study, which showed the product helped surgeons detect otherwise hidden tumors. * Repligen Corp., of Cambridge, Mass., signed an agreement to sell its Allegro Biologics business unit to Apotex USA Inc

Rorer, a subsidiary of Rhone-Poulenc Group in Paris, is conducting the trials to add stem cell transplants to the drug's label in Europe...Sheffield said it has an option on an exclusive license to Baylor's technology concerning ps20 and UGIF and has filed a U.S

Pharmacopeia initially filed to sell 2.25 million shares at $14 to $16 each. (See BioWorld Today, Oct. 20, 1995, p. 1.) * PRP Inc., of Watertown, Mass., said preliminary results from Phase II trials of its infusible platelet membranes (IPM) demonstrated the product controlled bleeding in thrombocytopenic patients and no adverse reactions were reported...Sheffield said it has an option on an exclusive license to Baylor's technology concerning ps20 and UGIF and has filed a U.S

Pharmacopeia initially filed to sell 2.25 million shares at $14 to $16 each. (See BioWorld Today, Oct. 20, 1995, p. 1.) * Researchers at Boston University said interleukin-16, formerly called lymphocyte chemoattractant factor, stimulates growth of CD4+ T cells, which are infected by HIV. * IDEC Pharmaceuticals Corp., of San Diego, is getting $1.5 million for expanding its marketing collaboration for IDEC-C2B8, a potential B cell lymphoma drug, with Genentech Inc., of South San Francisco, to

The agent was given to patients prior to chemotherapy...The drug is in Phase II studies in refractory pediatric patients. * IDEC Pharmaceuticals Corp., of San Diego, is getting $1.5 million for expanding its marketing collaboration for IDEC-C2B8, a potential B cell lymphoma drug, with Genentech Inc., of South San Francisco, to include Japan and other Asian countries

BioStar Inc., of Boulder, Colo., received FDA clearance to market its Optical ImmunoAssay chlamydia point-of- care test...Metra Biosystems Inc., of Mountain View, Calif., and Wyeth-Ayerst Laboratories, of Radnor, Pa., initiated a non-exclusive worldwide co-promotion collaboration related to the company's products to diagnose, treat and prevent osteoporosis...Initially, the plan is to increase education and awareness of bone disorders. (c) 1997 American Health Consultants

The trial will involve 10 to 20 ALS patients and six healthy volunteers, all of whom will receive 28 days of treatment. * Vertex Pharmaceuticals Inc., of Cambridge, Mass., reported positive data from a Phase I/II study of its anti- multidrug resistance compound, VX-710, in combination with the anti-cancer drug, doxorubicin...VX-710 is designed to prevent tumor cells' multidrug resistance gene from pumping out chemotherapeutics before they have a chance to work

The product is used to restore dermal tissue in burn patients. * Lidak Pharmaceuticals Inc., of La Jolla, Calif., raised $9 million in the first stage of a planned $15 million financing...VX-710 is designed to prevent tumor cells' multidrug resistance gene from pumping out chemotherapeutics before they have a chance to work

In addition to determining a maximum dose toleration for the drug, the trials will assess anti-tumor activity...Genta expects to file an investigational new drug application with the FDA next year to begin clinical studies in the U.S. * Lidak Pharmaceuticals Inc., of La Jolla, Calif., raised $9 million in the first stage of a planned $15 million financing

By inhibiting a complement response, the drug is designed to prevent the unleashing of cell- destroying enzymes, which when produced in excess can cause dangerous inflammation associated with such disorders as cardiac reperfusion, transplant rejection and respiratory ailments...Phase II trials of TP10 are expected to begin in 1996 for adult respiratory distress syndrome. * Lidak Pharmaceuticals Inc., of La Jolla, Calif., raised $9 million in the first stage of a planned $15 million financing...The

Phase II trials of the vaccine are expected to begin in 1996 in cystic fibrosis and chronic bronchitis patients. * Corvas International Inc., of San Diego, said preclinical studies of its thrombin inhibitor, which is derived from proteins produced by blood-feeding hookworms (ancylostoma caninum), showed the compound was effective and safe as an anti-blood- clotting drug...The buy-out is valued at between $12.50 to $13 per share...Phase II trials of TP10 are expected to begin in 1996 for adult

The drug is designed to bind to the CD2 receptor on the surface of immune system T cells. * Carrington Laboratories Inc., of Irving, Texas, signed an agreement with Mexico-based Laboratorios PiSA S.A...Phase II trials of TP10 are expected to begin in 1996 for adult respiratory distress syndrome. (c) 1997 American Health Consultants

The new company, which will focus on late-stage development and commercialization of new and formulated products in Asia, is 40 percent owned by Genelabs, 35 percent by the Taiwan government and 25 percent by private investors. (See BioWorld Today, July 18, 1995, p. 1.) * Guilford Pharmaceuticals Inc., of Baltimore, licensed rights to a biodegradable polymer from Yissum Research Development Corp...of the Hebrew University of Jerusalem, which it intends to develop for the delivery of drugs for

The work will broaden the company's gene therapy program for cancer by allowing in vivo administration of genes. * CoCensys Inc., of Irvine, Calif., completed a Phase I trial that showed ACEA 1021, a glycine-site N-Methyl- D-Aspartate receptor antagonist for stroke, was well tolerated and had no side effects. * Neurex Corp., of Menlo Park, Calif., said a Phase I/II study of SNX-111 for severe pain in seven patients showed the agent has potential to provide symptomatic relief in those who had

Serious infections occurred in 5 of 29 (17 percent) of infants given Leukine compared to 12 of 31 (39 percent) in the placebo group. * ImmunoGen Inc., of Cambridge, Mass., hired PaineWebber Inc., of New York, to help it achieve its partnering objectives. * IMRE Corp., of Seattle, said the FDA conditionally approved a 268-patient pivotal trial of its Prosorba column for the treatment of rheumatoid arthritis. * NeXstar Pharmaceuticals Inc., of Boulder, Colo., acquired patent rights to MiKasome